Trading a Stock’s Investigation


During a time in which many have been awaiting the release of a COVID-19 vaccine, many biotech companies have been working around the clock in order to develop and test a safe and effective vaccine.

While many companies have indeed trialed a vaccine and announced donations… Have some companies been lying about having a vaccine readily available in order to increase the price per share of their stock to sell their shares at a more valuable price?

Ticker Code Ticker Name Ticker Industry Price Change IV
AMZN Amazon Com Inc Internet Retail -7.60% 36.9 -7.9
AAPL Apple Inc Consumer Electronics -1.60% 33.7 -3.4
TSLA Tesla Inc Auto Manufacturers -10.30% 84.9 +10.0
BA Boeing Co Aerospace & Defense -5.40% 80.5 +6.7
MSFT Microsoft Corp Software – Infrastructure -2.60% 35.2 +3.6
GILD Gilead Sciences Inc Drug Manufacturers – General -4.80% 62.4 +0.8
XOM Exxon Mobil Corp Oil & Gas Integrated -7.20% 51.1 +2.4
DIS Walt Disney Co Entertainment -2.50% 46.6 +3.8
FB Facebook Inc Internet Content & Information -1.20% 35.7 +3.2
ZM Zoom Video Communications Inc Internet Content & Information 2.50% 90.7 +4.9
NFLX Netflix Inc Entertainment -1.10% 44.3 +0.8
DAL Delta Air Lines Inc Airlines -6.90% 79.5 +3.8
BAC Bank Of America Corp Banks – Global -4.00% 52.0 +5.5
INO Inovio Pharmaceuticals Inc Biotechnology -14.60% 220.8 +5.3
GE General Electric Co Specialty Industrial Machinery -4.40% 62.4 +4.8
CCL Carnival Corp Travel Services -12.40% 103.8 +4.9
F Ford Motor Co Auto Manufacturers -3.30% 74.0 +5.8
AMD Advanced Micro Devices Inc Semiconductors -4.80% 58.1 +4.4
T At&T Inc Telecom Services -1.90% 32.9 +1.0
V Visa Inc Credit Services -1.80% 39.1 +0.6

In February of 2020, Inovio Pharmaceuticals (NYSE: INO) CEO Joseph Kim had intentionally told Fox Business News that INO had developed a COVID-19 treatment, and INO’s price per share increased by 400% as a result.

That is until yesterday, when Citron Research announced that INO had not developed a COVID-19 treatment, and CEO Joseph Kim had intentionally misled shareholders by making false statements. The SEC immediately took notice, and INO is currently under investigation.

Through my decade of experience as an active trader, I’ve seen news items like this hit press wires countless times. What I’ve learned from events of this nature is that they can make for fast, exciting, and highly lucrative trading opportunities.

In my experience, if the SEC can prove that Joseph Kim did knowingly make false statements and mislead shareholders, INO’s share price may plummet, which would present a remunerative downside trading opportunity.

But what if the SEC finds no harm in Joseph Kim’s statement, and INO has indeed developed a COVID-19 vaccine? I expect price per share of INO to soar, which could supply a profitable bullish trading opportunity.

While we may not know the result of the SEC’s current investigation today, the chart does look ready to trade from both a bullish and bearish point of view.

Since March 13th of 2020, INO has only closed below its 20-day simple moving average line twice, and the stock has been in a steady uptrend through what has been a volatile market.

Shown in green in the chart above, the 20-day simple moving average line is what I’ll be monitoring to trade INO today.

Should INO trade above its 20-day simple moving average line, I’ll be interested in making a bullish trade looking for fast profits.

Below its 20-day simple moving average line, I’ll be interested in shorting INO in an effort to collect all available profits by the end of the day.

Yours for TrackStar trading,

Davis Martin
America’s #1 Premarket and Day Trader

Disclaimer: This is not investment advice. This article is for information purposes only and opinion-based on financial advisor data across a selection of websites. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions.